Wolfgang Miesbach: The Growing Impact of Age-Related Disease in Hemophilia
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared post on LinkedIn:
“Crucial real-world data on our aging haemophilia population!
As life expectancy improves, our patients face new clinical challenges.
A massive Emory University analysis of US Medicare claims (2000-2020) looking at 2,058 adults (avg age 57.2; 1,735 Hem A or 323 Hem B) reveals critical shifts:
- Surging Comorbidities: Rates of arthropathy (the highest burden by far), liver disease, CVD, and renal disease are substantially higher in haemophilia patients vs. the matched US population.
- Elevated Mortality: Males with haemophilia face a 12% higher mortality rate (aHR is equal to 1.12) vs. the general public. (No significant difference in females: aHR is equal to 0.96).
- The Multiplier Effect: Having common chronic diseases (Cancer, COPD, CHF, CVD, Diabetes) drives a massive 67–300% increase in mortality rates for these patients.
We are managing the first true cohort of aging haemophilia patients. This data screams for a shift toward proactive, multidisciplinary prevention to tackle age-related chronic diseases alongside core bleeding risks.
Kudos to Stacey Fedewa, Christine Kempton, MD, MSc, and the Emory, Hemophilia of Georgia team for this excellent work!”

Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 19, 2026, 16:27263 PolyU Students and Staff Unite to Donate Blood – Hong Kong Red Cross Blood Transfusion Service
-
Nov 19, 2026, 16:16Billy Otieno: The Future of Blood Donation Lies Beyond Collection
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing
-
Nov 19, 2026, 14:19Long-Read Sequencing Is Closing Diagnostic Gaps in Inherited Bleeding Disorders
-
Nov 19, 2026, 13:36Raja Prince: Protein S Silencing and the Future of Hemostatic Therapy
-
Nov 19, 2026, 13:26M. Sekip Altunkan: The Thrombotic Risk of Andexanet Alfa
-
Nov 19, 2026, 13:18Felice Gragnano: Personalizing Antiplatelet Therapy After PCI
-
Nov 19, 2026, 13:11When Postpartum Warning Signs Are Ignored – National Blood Clot Alliance